Quarterly ResultMay 6, 2026, 06:32 AM
Elanco Q1 Revenue $1.37B, Adj EPS $0.40; Raises Full Year Outlook
AI Summary
Elanco Animal Health reported strong first quarter 2026 results with revenue of $1.37 billion, a 15% increase year-over-year, and adjusted EPS of $0.40, up 8%. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and improved its year-end net leverage ratio target. Key product highlights include Zenrelia™ achieving blockbuster status and Credelio Quattro™ gaining market share, alongside new product launches and retail customer additions.
Key Highlights
- Q1 2026 Revenue: $1.37 billion, up 15% YoY (10% organic constant currency).
- Q1 2026 Adjusted EPS: $0.40, up 8% YoY.
- Q1 2026 Adjusted EBITDA: $334 million, up 21% YoY.
- Full Year 2026 Revenue guidance raised to $5.01B-$5.085B.
- Full Year 2026 Adjusted EPS guidance raised to $1.03-$1.09.
- Year-end net leverage ratio target improved to 3.0x-3.2x Adjusted EBITDA.
- Zenrelia™ achieved trailing 4-quarter blockbuster status.
- Acquisition of AHV International closed on April 30th.